Dr. John P. Seibyl, MD

Expert Publications

• Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans.
• Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
• Effect of injection time on postictal SPET perfusion changes in medically refractory epilepsy.
• Single-photon emission computed tomography of the dopamine transporter in parkinsonism.
• Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine.
• Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans.
• Reproducibility of serial peri-ictal single-photon emission tomography difference images in epilepsy patients undergoing surgical resection.
• Decreased cerebral blood flow during seizures with ictal SPECT injections.
• Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT.
• Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans.
• Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT.
• SPECT imaging with the D(4) receptor antagonist L-750,667 in nonhuman primate brain.
• Ratio-images calculated from interictal positron emission tomography and single-photon emission computed tomography for quantification of the uncoupling of brain metabolism and perfusion in epilepsy.
• Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates.
• Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers.

Media Releases

Get to know Nuclear Medicine Physician Dr. John P. Seibyl, who serves patients in New Haven, Connecticut.

Dr. Seibyl, a board-certified nuclear medicine physician, serves as the Executive Director, Senior Scientist, and Chairman of the Board at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. 

In 2001, he co-founded the Institute for Neurodegenerative Disorders alongside Dr. Kenneth Marek as a non-profit, independent clinical imaging research facility. Their goal was to create a unique clinical research company that combines excellence in clinical neuroscience with state-of-the-art imaging to develop improved tools for the diagnosis and treatment of Parkinson’s disease, Alzheimer’s disease, and other neurologic conditions. Along with a team of expert researchers, the facility is actively involved in novel clinical studies, offering the potential to slow neurological disease or even restore neurological function.

Recognized as an international expert on PET and SPECT imaging for neurodegenerative disorders, Dr. Seibyl also serves as the Managing Director of Molecular NeuroImaging, a Division of inviCRO, and as the Chairman of the Board & President of the Trinity Institute For Applied Neuroscience And Spirituality.

Prior to his current endeavors, he served as the Co-Founder & President of Molecular NeuroImaging, the Director of the NeuroSPECT Center at Yale University, the Chief of the Section of Nuclear Medicine and Director of the Yale PET Center (1996-2001), and an Associate Clinical Professor of Diagnostic Radiology at Yale University School of Medicine. 

After earning his medical degree from the Case Western Reserve University School of Medicine in 1986, Dr. Seibyl trained as a post-doctoral fellow in the Department of Psychiatry at Yale University, where he won the Seymour Lustman Research Prize for two consecutive years. He then joined the faculty as an Assistant Professor upon the completion of his training. 

While on the psychiatry faculty, his interest in brain imaging led to his returning for a training fellowship in nuclear medicine at Yale under Dr. Paul Hoffer. He was recruited to the Diagnostic Radiology faculty and was appointed the Director of the NeuroSPECT Center, a clinical brain imaging research lab in the Section of Nuclear Medicine. He subsequently became Chief of the Section of Nuclear Medicine and Director of the Yale / VA PET Center.

The doctor is board-certified in nuclear medicine by the American Board of Nuclear Medicine, which certifies physicians as specialists in the practice of nuclear medicine. In addition, he is board-certified in psychiatry by the American Board of Psychiatry and Neurology, which is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and maintenance of certification processes.

To stay current with the latest advances in his field, Dr. Seibyl remains a distinguished member of the Society of Nuclear Medicine and Molecular Imaging, the Brain Imaging Council, and the Society of Nuclear Medicine-New York Chapter – from all of which he is a former President. He was awarded the 2015 Kuhl-Lassen Award by the Society of Nuclear Medicine and Molecular Imaging for outstanding contributions to the advancement of molecular imaging. 

Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear medicine physicians are medical specialists who use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy.

With an impressive professional journey that spans over three decades, Dr. Seibyl has won numerous grants and contracts in the context of his work in brain imaging, publishing over 250 articles, book chapters, and case reports. He serves on the editorial board of the European Journal of Nuclear Medicine and is a frequent reviewer for top-tier nuclear imaging journals. 

Furthermore, he serves on international panels for his work in neurodegenerative disease imaging, working closely with Dr. Marek to establish the NeuroSPECT Center as the premier Parkinson’s disease brain imaging research center in the world. Recent projects include the development of a web-based normal brain image database, and on-going work applying brain imaging techniques and analytic methods to improve the diagnosis and assessment of disease status in patients with neurodegenerative diseases.

With a passion for his field, Dr. Seibyl attributes his success to his ability and interest to continue learning and find new details about the brain. In his free time, he enjoys distance running.

Recommended Articles

• 5 Facts You Never Knew About Genital Herpes

  Genital herpes is one of the most common sexually transmitted infections (STI) in the United States that mostly affects people between 14 and 49. It occurs as a result of infection with both types of herpes simplex virus (HSV)-HSV1 and HSV2. However, most people with genital herpes are infected with...

• What Does Bactrim Treat?

  BactrimBactrim is a combination of antibiotics called trimethoprim and sulfamethoxazole, which help treat different types of bacterial infections. Bactrim can be used for the treatment of urinary tract infections (UTIs), ear infections, bronchitis, shigellosis, traveler's...

• Is the Atkins Diet Effective?

  The Atkins diet, created by cardiologist Robert C. Atkins, is a very popular low-carbohydrate diet. This diet claims to have several benefits including weight loss, reduced appetite, better heart health and improved memory. The theory behind this diet is that obesity results from overeating...

• The Burden of ADHD

  Although a child might not feel any different after being diagnosed with ADHD, the diagnosis truly affects his or her parents. For parentsYou will probably require special training by a specialist in ADHD to learn how to cope with your child’s condition. The specialist who diagnosed your child...

• Comparative Value of PARP Inhibitors is Lacking, According to ICER Report

  The Institute for Clinical and Economic Review, also known as ICER, is a non-profit organization that analyzes the value of new medical tests, treatments, and drugs approved by the U.S. Food and Drug Administration (FDA). The goal of ICER is to use the value of these innovations and develop reports...

• The History of Muscular Dystrophy

  What is muscular dystrophy?Muscular dystrophy is an inherited disorder, which is often characterized by a progressive type of muscular degeneration and weakness. There are several types of muscular dystrophy, wherein each type eventually leads to an increased disability, strength loss, and potential...